Every 8-K that Yarrow Bioscience, Inc. (YARW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow YARW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full YARW filings page.
Yarrow Bioscience, Inc. (YARW) entered into an underwriting agreement on September 10, 2026 to conduct a primary public offering of its common stock. The company agreed to issue and sell 5,769,231 shares at a public offering price of $26.00 per share, with Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC acting as representatives of the underwriters.
The underwriters received a 30‑day option to purchase up to an additional 865,384 shares, which they exercised in full on September 11, 2026. Yarrow Bioscience expects net proceeds of about $161.8 million from the offering, including the option shares, after underwriting discounts, commissions and estimated expenses. The transaction is being conducted under an effective shelf registration statement on Form S‑3, with a final prospectus supplement dated September 10, 2026, and is expected to close on September 14, 2026.
The underwriting agreement includes customary representations, conditions and indemnification provisions. The company’s directors and executive officers have entered into 60‑day lock‑up agreements, limiting sales or other dispositions of common stock without prior written consent of Jefferies LLC and TD Securities (USA) LLC.
Yarrow Bioscience, Inc. (YARW) filed a Form 8-K to furnish an updated corporate overview and Business description following its merger with Yarrow Bioscience Operating Company Corp. and to provide an investor presentation focused on lead antibody YB-101 for Graves’ disease (GD) and thyroid eye disease (TED).
The company highlights YB-101 as a potential first-in-class anti-TSHR biologic with Fast Track Designation in GD, now in a combined Phase 2a/2b GD trial initiated in June 2026, supported by Phase 1 TED data from partner GenSci in China. Yarrow details a global license from GenSci, including a $70 million upfront payment, up to $1.295 billion in milestones, and tiered royalties in the low to low‑mid teens on ex‑China sales. The company reports $200 million raised to date and states its cash runway is expected to fund operations into 2028.
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) filed an amended report to provide full historical and pro forma financial information for the July 27, 2026 merger with privately held Yarrow Bioscience, Inc. (now Yarrow Bioscience Operating Company Corp.). The company is a clinical-stage biotech developing YB-101, a monoclonal antibody targeting the thyroid stimulating hormone receptor for Graves’ disease and thyroid eye disease.
Pre-Merger Yarrow raised $100.0 million in Series A funding in December 2025 and paid a $70.0 million upfront fee to GenSci for an exclusive ex-China license to YB-101, with up to $1.295 billion in potential milestones and tiered royalties in the low to low‑mid teens. It recorded a net loss of $71.0 million from inception to December 31, 2025 and a further $9.3 million loss for the six months ended June 30, 2026.
Cash was $100.0 million at December 31, 2025 and $18.7 million at June 30, 2026, before considering $100.0 million of pre‑closing financing. Management states this liquidity is expected to fund operations for at least 12 months. The merger is accounted for as a reverse recapitalization with Yarrow as the accounting acquirer, based on an exchange ratio of 0.7171 VYNE shares per Yarrow share.